KALARIS THERAPEUTICS, INC.
Income Statement
| Line Item | FY2019 |
|---|---|
| Revenue | $165.0K |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $16.2M |
| SG&A Expense | $10.6M |
| Operating Income | $-26.7M |
| Operating Margin | -16,182.4% |
| Interest Expense | — |
| Pretax Income | $-23.8M |
| Income Tax Expense | — |
| Net Income | $-23.8M |
| Net Margin | -14,447.9% |
| EPS (Basic) | $-1.69 |
| EPS (Diluted) | $-1.69 |
| Shares Outstanding (Basic) | 23.1M |
| Shares Outstanding (Diluted) | 23.1M |
| Dividends Per Share | — |